Press release
Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the C Bronchitis Treatment Landscape. Click here to read more @ Bronchitis Pipeline Outlook [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bronchitis Pipeline Report
* In April 2025, Incyte Corporation announced a study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
* In April 2025, Kadmon, a Sanofi Company announced a Phase 2, open-label, long-term treatment and follow-up study in subjects with cGVHD who have been previously treated with belumosudil in Study KD025-208 or Study KD025-213. Subjects will not be screened.
* DelveInsight's Bronchitis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchitis treatment.
* The leading Bronchitis Companies such as Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp & Dohme Corp., Johnson & Johnson Pharmaceutical Research & Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott and others.
* Promising Bronchitis Pipeline Therapies such as BN101, TQ05105 Tablet, Belumosudil, Rituximab, Prednisone, TDI01 suspension, INCA034176, Corticosteroids and others.
Discover groundbreaking developments in Bronchitis Therapies! Gain in-depth knowledge of key Bronchitis Clinical trials, emerging drugs, and market opportunities @ Bronchitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchitis Emerging Drugs Profile
* DW 1601: Daewon Pharmaceutical
Daewon Pharmaceutical is developing DW 1601 for the treatment of Bronchitis.
The Bronchitis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchitis Treatment.
* Bronchitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchitis Market
Stay informed about the Bronchitis Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Bronchitis Unmet Needs [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchitis Companies
Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp & Dohme Corp., Johnson & Johnson Pharmaceutical Research & Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott and others.
Bronchitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
Bronchitis Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
Transform your understanding of the Bronchitis Pipeline! See the latest progress in drug development and clinical research @ Bronchitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bronchitis Pipeline Report
* Coverage- Global
* Bronchitis Companies- Zambon SpA, Yuhan Corporation, Theravance Biopharma, Genentech, Inc., GlaxoSmithKline, Novartis, SolAeroMed Inc., Reata Pharmaceuticals, Inc., Pulmatrix, Pharmaxis, PharmaKing, NovaBiotics, Merck Sharp & Dohme Corp., Johnson & Johnson Pharmaceutical Research & Development, Ionis Pharmaceuticals, Inc., Incyte Corporation, EmeraMed, Daewon Pharmaceutical Co., Ltd., Chong Kun Dang Pharmaceutical, Breath Therapeutics Inc., Boehringer Ingelheim, BioMarck Pharmaceuticals, Beyond Air, AstraZeneca, APT Pharmaceuticals, Inc., Abgenix, Abbott and others.
* Bronchitis Pipeline Therapies- BN101, TQ05105 Tablet, Belumosudil, Rituximab, Prednisone, TDI01 suspension, INCA034176, Corticosteroids and others.
* Bronchitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Respiratory Disease Research-Access the Full Bronchitis Pipeline Analysis Today! @ Bronchitis Drugs and Companies [https://www.delveinsight.com/sample-request/bronchitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Bronchitis: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
* Pipeline Therapeutics
* Comparative Analysis
* Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
* Bronchitis - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Bronchitis companies' collaborations, Licensing, Acquisition -Deal Value Trends
* Bronchitis Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
* Late Stage Products (Phase III)
* Comparative Analysis
* DW 1601: Daewon Pharmaceutical
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Inactive Products
* Comparative Analysis
* Bronchitis Key Companies
* Bronchitis Key Products
* Bronchitis- Unmet Needs
* Bronchitis- Market Drivers and Barriers
* Bronchitis- Future Perspectives and Conclusion
* Bronchitis Analyst Views
* Bronchitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchitis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bronchitis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 4000134 • Views: …
More Releases from ABNewswire
ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA App …
DelveInsight's, "ER positive, HER2 negative Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Mastocytosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechani …
DelveInsight's, "Mastocytosis Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mastocytosis pipeline landscape. It covers the Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the…
Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of …
DelveInsight's, "Asthma Pipeline Insight 2025" report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Asthma Research. Learn more about our…
Cystic Fibrosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mech …
DelveInsight's, "Cystic Fibrosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding…
More Releases for Bronchitis
Bronchitis Market: Study Navigating the Future Growth Outlook
Global Bronchitis Market Report 2019 - Market Size, Share, Price, Trend and Forecast is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Bronchitis Market. Some of the key players profiled in the study are…
Bronchitis Treatment Market: Rising Morbidity & Mortality Rate Leads to Dominanc …
Cough has been one of the most common illness-related reason for ambulatory visits in the United States. As the cough linked with bronchitis is so troublesome and slow to resolve, patients seek treatment. The use of biomarkers in identifying patients who might reap benefit from antibiotics is popular. However, the American Academy of Pediatrics cautions against the use of use of antibiotics for apparent viral respiratory illness, including pharyngitis, bronchitis…
Global Bronchitis Drug Market Professional Survey Report 2018
This report studies Bronchitis Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
Request Sample Copy of the Business Report @ https://www.worldwidemarketreports.com/sample/111008
This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Advanced Inhalation Therapies (AIT) Ltd,AstraZeneca Plc,DBV Technologies…
Trends in the Bronchitis Treatment Market 2016-2026
The chronic bronchitis is defined as the inflammation of the bronchi that lasts for more than 3 months for consecutive 2 years. The bronchi are the tubes which carry air in to the lungs. The major symptom of bronchitis is persistent cough associated with mucus expectoration, headache, nasal congestion, sore throat and fatigue. Risk factors for bronchitis include irritants, chemicals, air pollution and smoke. There are mainly two types of…
Chronic Bronchitis - Pipeline Research and Markets Insight, 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Chronic Bronchitis - Pipeline Insight, 2017”. This report provides comprehensive insights of the ongoing therapeutic research and development across Chronic Bronchitis.
Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265427
The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Chronic Bronchitis by development stage, therapy…
Bronchitis Treatment Market Segments And Key Trends 2016-2026
The chronic bronchitis is defined as the inflammation of the bronchi that lasts for more than 3 months for consecutive 2 years. The bronchi are the tubes which carry air in to the lungs. The major symptom of bronchitis is persistent cough associated with mucus expectoration, headache, nasal congestion, sore throat and fatigue. Risk factors for bronchitis include irritants, chemicals, air pollution and smoke. There are mainly two types of…
